Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PRV

- PMLiVE

Smart watch epilepsy monitor cleared by FDA

Approval could potentially clear the way for insurers to reimburse its cost

dengue fever mosquito

Takeda gets FDA fast-track status for Zika vaccine

The phase I candidate also has the backing of US federal funding body BARDA

Sanofi reception

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

The offer comes at a 110% premium on the Belgian biopharma’s share price

- PMLiVE

Dominique Carouge joins Sanofi as head of business transformation

He also becomes a member of the executive committee

Sanofi reception

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

French pharma firm offers $105 apiece for the spin-out’s shares

- PMLiVE

Novartis gets speedy reviews for new Kymriah filings

US and EU regulatory agencies will review the drug for DLBCL patients

- PMLiVE

AZ and Merck & Co get FDA breast cancer nod for Lynparza

It becomes the first PARP inhibitor to be approved outside ovarian cancer

Sanofi reception

Sanofi and Regeneron ramp up immuno-oncology collaboration

Will put an additional $1bn in investigational candidate cemiplimab

- PMLiVE

FDA’s year-end approvals take annual tally to 46

Rhopressa and Steglatro were among the final medicines licensed last year

Sanofi reception

FDA lifts clinical hold on Sanofi’s haemophilia drug

Phase II and III trials of fitusiran can now resume

Sanofi reception

Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

The pharma partners begin with a skin cancer filing to the US FDA

Sanofi reception

Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

The pharma partners begin with a skin cancer filing to the US FDA

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links